



1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

*Friday 6th and Saturday 7th September 2013,
Shanghai*



*The little mermaid,
Copenhagen, Denmark*



*European Commission
building, Brussels, Belgium*



*Duomo cathedral,
Milan, Italy*




*The oriental pearl tower,
Shanghai, China*



*The Eiffel Tower,
Paris, France*



*The town hall,
Hannover, Germany*



1st Sino-Euro Experts Conference on Immune
Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013,
Shanghai

WELCOME LETTER

On behalf of the Organizing Committee of the 1st Sino-Euro Expert Conference on Immune Biomarkers for Personalized Medicine in Oncology – 2nd Forum on Translational Medicine, it gives us great pleasure to extend a warm welcome message to all of you who attend this conference in this wonderful and cosmopolitan city of Shanghai.

The conference combine the united effort of all partners organizations to continue positioning multidisciplinary and personalized medicine as the ways forward to improve the treatment of cancer patients. The joint institute Fudan University Shanghai Cancer Center – Institut Merieux laboratory (FDUSCC-IM), created in 2006, is conducting ambitious scientific research projects on oncology in China through a long term partnership between Fudan University Shanghai Cancer Center, Transgene and bioMerieux. New European partners (Hannover Medical School, Fondazione IRCCS Istituto Nazionale Dei Tumori and University of Copenhagen) have joined FDUSCC and Transgene to launch an ambitious international program IMMUNOCAN in order to enhance current research activities of the joint institute and to create durable links between Chinese and European teams.

This 1st Sino-Euro Expert Conference on Immune Biomarkers for Personalized Medicine in Oncology – 2nd Forum on Translational Medicine is an unique opportunity to share scientific and medical Sino-Euro knowledge on Immune biomarkers to emphasize the management of cancer patients particularly those with non-small cell lung cancer, colorectal cancer, breast cancer and hepatocarcinoma.

Specific sessions will focus on immunotherapy, peripheral blood biomarkers, tumor microenvironment, the role of NK cells in cancer progression and the traditional Chinese medicine for cancer treatment. A dedicated session will promote the research activities of the FDUSCC-IM joint institute.

International experts from all over China, Europe and USA will be involved in giving lectures, on the latest trends and frontiers of research and achievements on Biomarkers for personalized medicine & translational medicine.

Of course, we ensure that you have enough time to exchange and develop interpersonal networks to promote cooperation. We are confident that together we will advance this and push the boundaries of the immune Biomarkers for Personalized Medicine in Oncology and translational medicine.

Thanks to all presenters for your fine work in this area, and to our colleagues from FDUSCC and sponsors for their help in staffing this Conference.

We wish all of you an unforgettable Conference and a most enjoyable stay in Shanghai!

邵志敏

Henri Liden

FUDAN UNIVERSITY SHANGHAI CANCER CENTER



Fudan University Shanghai Cancer Center (FUSCC), under the auspice of the Ministry of Health, is a tertiary hospital (Grade A), engaged in clinical practice, medical education, oncological research and cancer prevention. Historically, it can be traced back to Sino-Belgian Radium Institute established on March 1, 1931 as the earliest hospital of oncology in China.

A Record High in Clinical Practice

At present, FUSCC is staffed with 1608 medical workers, and equipped with 1205 beds (in 2012). Annually, FUSCC receives 932,000 outpatients (including emergency cases), 40,600 inpatients, 23,000 surgeries performed, and 6,484 patients for

radiotherapies (900 daily). The multidisciplinary therapies offered at FUSCC involve the medical teams on more than twelve disciplines so that clinical and disciplinary constructions are improved and new oncological concepts and guidelines are developed. The arduous efforts are intended to treat the patient as precisely as possible, administer standard chemotherapies and advance therapeutic efficacy.

Achievements and Accomplishments in Research

At FUSCC, oncology and clinical pathology are highly recognized as key academic disciplines by the Ministry of Education, pathology and integration of traditional and western medicine, as key clinical specialties. Breast cancer oncology, radiotherapy,

pathology are formally acknowledged as key clinical disciplines by the Ministry of Health. Two medical centers are municipally established for radiotherapy and breast cancer, respectively, with clinical pathology municipally recognized as a key medical discipline. In Shanghai, FUSCC serves as the Center for Pathological QC, the Center for Radiotherapeutic QC, and the Center for Chemotherapeutic QC, respectively. To FUSCC is also attached Shanghai Anti-Cancer Association. In addition, FUSCC is armed with such institutions as the National Drug Clinical Trials authorized by State Food and Drug Administration; the Key Laboratory on Breast Cancer in Shanghai (under construction); Cancer Institute of Fudan University, the Institute on Breast Cancer, Fudan University; the Institute on Pancreatic Cancer, Fudan University; and Fudan University Pathology Institute.

In 2012, FUSCC enrolled 44 MS and 56 MD students, turning out 36 MS and 38 MD graduates. In research, FUSCC won 144 projects, with a total sum of RMB54,480,000.00, of which 39 were derived from The National Natural Science Fund in the total amount of RMB17,010,000.00. Its team of the basic and clinical research on breast cancer was honorably listed as a pioneering one for further development by the Ministry of Education; its key laboratory on breast cancer in Shanghai received the project approval. In documentation, FUSCC had 332 medical papers published, 173 registered in SCI, with a total of 564 impact factors; and two monographs published, winning 7 patents and 5 scientific awards at a ministerial level.

Academic and Clinical Exchanges at Home and Abroad

Deeply committed to conducting academic exchanges and cherishing its image of high prestige, FUSCC is actively engaged in collaborations at home and abroad so as to expand quality service across the

country. In 2012, FUSCC established collaborations with its counterparts at home. For instance, it set up a regional clinical pathological diagnosis center in Ningbo, Zhejiang Province. Since 2003, FUSCC has become a sister hospital with MD Anderson Cancer Center, the University of Texas in the USA, National University Cancer Institute in Singapore, Gustave-Roussy Cancer Center in France, Cancer Research Institute of Kanazawa University in Japan, the National Institute of Cancer Research in Italy. Thus, the academic and clinical exchanges have promoted FUSCC towards the frontier of oncology in the world.

Hospital Administration

FUSCC sticks to its commitment to the public good by practicing the patient-centered paradigm for total quality improvement and overall patient satisfaction, and by enhancing its administration and informationization for standard payments, efficient flows of service and convenient facilities. Its primary goal is to raise the quality of service, improve overall patient satisfaction and promote practice evaluation.

FUSCC is advancing at full speed. As a part of "the 12th National Five-year Plan," FUSCC is to have Proton & Heavy Ion Center. As another, FUSCC will have a research-integrated building set up so that the total number of beds can hit 2000. For all these is to be constructed the management model of group hospital.

FUSCC is deeply committed to treating the patients from different parts of the world, with the well-qualified staff, excellent skills, advanced equipments, scientific management, and life-friendly environment.



1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai

AGENDA

Agenda of 6th September

Time	Speakers	City, Country	Title
	Conference Chairs: Zhiming SHAO/Wolf-Herve FRIDMAN	PRC France	
8:30-9:00	Chair: Zhiming SHAO	Opening Ceremony	
8:30-8:35	Zhenghong YUAN	Shanghai, PRC	Welcome Speech
8:35-8:40	Emmanuel LENAIN	General Consul of France Shanghai, PRC	Welcome Speech
8:40-8:45	Romain MICOL	On Behalf of IMMUNOCAN Consortium	IMMUNOCAN Program Introduction
8:45-8:55	Official Photo		
9:00-10:10	Chairs: Jean-Yves BLAY Youlin QIAO	Session 1: Public health, Medical Management of Solid Cancers in Europe and in China	
9:00-9:30	Jean-Yves BLAY	Lyon, France	Epidemiology: Current and Future of Standard of Care
9:30-10:00	Youlin QIAO	Beijing, PRC	Epidemiology: Attributable Causes of Cancer in China
10:00-10:10	DISCUSSION		
10:10-11:20	Chairs: Zefei JIANG Rosaria ORLANDI	Session 2: Peripheral Blood Biomarkers	
10:10-10:30	Zefei JIANG	Beijing, PRC	Circulating Tumor Cells Predict Progression-Free and Overall Survival in Chinese Patients with Metastatic Breast Cancer, HER2-positive or Triple-negative (CBCSG004): a Multi-center, Double-blind, Prospective Trial.
10:30-10:50	Massimo CRISTOFANILLI	Philadelphia, USA	Defining the Role of Circulating Tumor Cells (CTCs) in the Liquid Phase of Epithelial Tumors
10:50-11:10	Paola ALLAVENA	Milan, Italy	Inflammatory Chemokines and Cytokines as Prognostic Markers for Human Colorectal Cancer
11:10-11:20	DISCUSSION		
11:20-12:00	Joint Lab Visit Tour		
12:00-13:30	Networking Lunch		
13:30-16:40	Chairs: Wolf-Herve FRIDMAN / Jian ZHANG	Session 3: Tumor Microenvironment	
13:30-14:00	Wolf-Herve FRIDMAN	Paris, France	Clinical Impact of the Immune Microenvironment of Primary and Metastatic Human Tumors
14:00-14:20	Jian ZHANG	Guangxi, PRC	Targeting CCL2/CCR2 Axis in Tumor Microenvironment
14:20-14:40	Elda TAGLIABUE	Milan, Italy	Understanding Tumor-Stromal Interactions: the New Trust for Beating Cancer
14:40-15:00	Paul HOFMAN	Nice, France	Crosstalk Between Neutrophils and Epithelial Cells: A New Role of the Innate Immunity in Tumor Initiation and Progression
15:00-15:10	DISCUSSION		
15:10-15:30	Networking Coffee Break		
15:30-15:50	Lionel APETOH	Dijon, France	Th17 Cells Differentiation and Anticancer Immune Response
15:50-16:10	Gaoxiang GE	Shanghai, PRC	Cancer- An Overheating Wound: Lysyl Oxidase in Lung Fibrosis and Cancer
16:10-16:30	Joy BURCHELL	London, UK	Aberrant Glycans as Circulating and Tumours Prognostic Markers in Breast Cancer
16:30-16:40	DISCUSSION		

04

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai

16:40-18:00	Chairs: Jin LI Roland JACOBS	SESSION 4: Role of NK Cells in Cancer Progression	
16:40-17:00	Adelheid CERWENKA	Heidelberg, Germany	Harnessing Natural Killer Cells against Cancer
17:00-17:30	Daniel OLIVE	Marseille, France	Recognition and Escape Mechanisms of Breast Tumor to NK cells
17:30-17:50	Heike KIELSTEIN	Halle, Germany	NK Cell Functions in Obesity and Cancer
17:50-18:00	DISCUSSION		
18:00-18:45	Keynotes Lectures Session		
18:00-18:20	Dominique STOPPA-LYONNET	Paris, France	Keynotes: Ethical Considerations in Predictive and Prognosis Biomarkers Research
18:20-18:35	Laurent BOCHEREAU	Brussels, Belgium	EU-China S&T Cooperation: Assets & Challenges
18:35-18:45	DISCUSSION		

Agenda of 7th September

Time	Speakers	City, Country	Title
8:30-9:40	Chairs: Nathalie ADDA Jean-Pierre ABASTADO	SESSION 5 : Immunotherapy	
8:30-8:50	Nathalie ADDA	Illkirch, France	New Immunotherapy Approches to Treat Cancer: Two Transgene's Clinical Development
8:50-9:10	Jean-Pierre ABASTADO	Singapore	Can We Improve the Traffic of Lymphocytes to the Tumor?
9:10-9:30	Maria Grazia DAIDONE	Milan, Italy	Potentials and Pitfalls of Circulating Biomarkers: from CTC to mRNA
9:30-9:40	DISCUSSION		
9:40-10:50	Chairs: Zhiqiang MENG Romain GINESTE	SESSION 6: Traditional Chinese Medicine for Cancer Treatment	
9:40-10:00	Hongxi XU	Shanghai, PRC	Anticancer Compounds from Medicinal Plants
10:00-10:20	Zhiqiang MENG	Shanghai, PRC	Application of Chinese Medicine in Liver and Pancreatic Cancer
10:20-10:40	Hailei ZHAO	Shanghai, PRC	The Application of TCM Syndrome Differentiation to the Cancer Treatment
10:40-10:50	DISCUSSION		
10:50-11:10	Networking Coffee Break		
11:10-11:45	Chairs: Xia MENG Christian BRECHOT	SESSION 7: FDUSCC-IM Joint Institute Research Activities	
11:10-11:20	Xun YE	Shanghai, PRC	Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
11:20-11:30	Romain MICOL	Illkirch, France	Activated NK Cells and Cytokines Signature in Stage IV NSCLC Chinese Patients: a Prognostic Study
11:30-11:40	Romain GINESTE	Shanghai, PRC	IMMUNOCAN Program for Colorectal & Breast Cancers
11:40-11:45	DISCUSSION		
11:45-12:50	Chairs: Weiguo HU Ting XU	2nd Forum on Translational Medicine	
11:45-12:05	Ting XU	Suzhou, PRC	Targeted Tumor Immunotherapeutic Development Through Antibody Engineering
12:05-12:25	Weiguo HU	Shanghai, PRC	Membrane Complement Regulatory Protein CD59 Confers Cancer Cells Resistance to Antibody-based Therapy: Mechanism and Strategy
12:25-12:45	Jie LIU	Shanghai, PRC	From Bedside To Bench
12:45-12:50	DISCUSSION		
12:50-13:00	Chairs: Jiong WU Romain MICOL	Perspective and Official Close-Out	

05

CONFERENCE CHAIRMEN



Zhiming SHAO

Mr. Zhiming SHAO, M.D. supervisor, distinguished professor of Fudan University, is one of the first batch of distinguished professor of Chang Jiang Scholars. He presently serves as the director of Fudan University Cancer Institute and Breast Cancer Institute; executive director of the Shanghai Breast Cancer Center; chairman of department of surgery and department of breast surgery

in Fudan University Shanghai Cancer Center; chairman of Breast Cancer Society, China Anti-Cancer Association; chairman of Breast Cancer Society, Shanghai Anti-Cancer Association; chairman of the Eighth Asian Breast Cancer Society, and member of the St. Gallen 2013 international breast cancer consensus panel.

Prof. SHAO was selected as one of the "Top Hundred Academic leaders on Key Disciplines in Shanghai Health System" in 1998, and in the same year he won the first "MEIJI Dairies Corp Life Science Award" of Chinese Academy of Sciences, and the first Principal Award of University of California-Los Angeles, U.S. He was selected as one of the first batch of distinguished professor of Chang Jiang Scholars Program by National Ministry of Education. He was awarded the National Excellent Youth Foundation in 2000, the "Young and Middle-aged Expert with Outstanding Contribution" from National Ministry of Health in 2004, the "Top Ten Scientific and Technological Elite" and "Academic leader of Shanghai Health System" in 2005 and in 2006, the "Guanghua Youth Prize" of Chinese Academy of Engineering. In 2012, he was chosen as leader of selected innovative team of the Ministry of Education, the key laboratories of breast cancer of Shanghai, and the Shanghai Education Commission Type B Program of the Priority Project of Clinical Medical Centers.

Prof. SHAO engages in clinical and basic research for breast cancer for long time. His researches mainly focus on susceptibility gene and mechanisms of metastasis of breast cancer. He hosted and actualized in over 30 key basic research projects including National Excellent Youth Foundation, National Science Foundation, Key Project of National 10th 5-year Plan, Priority project on clinical medicine of Ministry of Health (2004-2006, 2007-2009, 2010-2012), 863 Projects, 211 Projects phase II, 985 Projects, 973 Projects and others provincial or ministerial projects. He has published nearly 350 papers about breast cancer research in China and abroad, over 100 of which is included by SCI and has been cited for more than 2800 times by the world's medical literature.



W.H. FRIDMAN

Mr. Wolf H. FRIDMAN is professor of Immunology at Paris Descartes University medical School in Paris, France. He received his M.D. and Ph.D. degrees from the University of Paris. After 10 years in the laboratory headed by Jean Dausset, he created his own laboratory at the Cancer Research Centre in Villejuif in 1976, then moved to Institut Curie in 1983 and is presently Director of the Cordeliers

Research Centre, a joint research structure between INSERM, University Paris Descartes and University Pierre et Marie Curie. He is also Consultant at European Hospital Georges Pompidou in Paris.

Dr Fridman's research interests have been focused around the role of the immune system in controlling human tumors and the biological functions of receptors for IgG antibodies, both through basic and translational approaches. He, and his team, identified the protein references which trigger the biological functions of the receptors for IgG. In particular, he identified and named the ITIM motif, an inhibitory motif common to many receptors.

His main contributions in cancer immunology stand up to 1969 when he published, with Francois Kourilsky, the first demonstration of an immune response of the patient to his own cancer, in acute leukemia. He, then, focused on the analysis of the tumor microenvironment with the demonstration of the beneficial effect of a Th1 oriented immune response to control clinical outcome in cervical cancer. Since 2005, the studies of Jerome Galon, Franck Pages and Wolf H. FRIDMAN have changed the paradigm of host/cancer interactions by demonstrating that the 'immune contexture', taking in account the functionality, the location and the density of the immune infiltrate in colorectal tumors, is the major prognostic factor for human cancers. These findings really open the way for immune-based tools for efficient prognosis and therapy of cancers.

Professor Wolf Herve FRIDMAN is a co-author of more than 400 original peer-reviewed publications in journal which include Nature, Science, New England Journal of Medicine, Immunity Journal of Experimental Medicine, Journal of Clinical Investigation, Journal of Clinical Oncology, Gastroenterology, Blood, Proceedings of the Natural Academy of Sciences, Cancer Research, Journal of Immunology, European Journal of Immunology, Oncogene, Clinical Cancer Research, British Journal of Haematology, etc.

GUEST



Laurent BOCHEREAU

Keynotes Lectures Session

Position & affiliation: Head of Unit "Policy coordination, EFTA and enlargement, Russia, Asia and Pacific", European Commission Brussels, Belgium

Topic title: EU-China S&T Cooperation: Assets & Challenges

Laurent BOCHEREAU is responsible for the "Policy coordination" Unit within the International Cooperation Directorate of the European Commission's Directorate General for Research and Innovation and is also Acting Director for the International Cooperation Directorate since January 2013. He gained a Laureate from the Ecole Polytechnique and ENGREF in Paris, a Master's degree from the University of California and a Ph.D. from the University of Paris VI. After spending several years working as a research project leader at IRSTEA, he served two years in the French Ministry for Research. He joined the European Commission in 1995 where he worked several years as assistant to the Director for Life Sciences and then as Head of Unit with responsibilities for agriculture, forestry, agro-industry and food safety research. From 2007 to 2010, he was the Head of the "Science, Technology and Education" Section at the Delegation of the European Union in Washington DC.



Dominique STOPPA-LYONNET

Keynotes Lectures Session

Position & affiliation: Head of Constitutional Genetic Department, Institut Curie and National Ethics Advisory Committee, Paris, France

Topic title: Ethical Considerations in Predictive and Prognosis Biomarkers Research

Professor of Medical Genetics, University Paris Descartes and Head of Genetics Department at Institut Curie

University career: M.D., Former Intern in the Hospitals of Paris (1982 entrance examination), Ph.D. in Genetics, 1990 and professor of Medical Genetics, University Paris Descartes, 2007. Main Membership of scientific associations and working parties: genetics and Cancer Group of the FNCLCC (Federation of French Cancer Centres), French National Consultative Ethics Committee, president of the scientific committee of ADECA 75 (Association for cancer screening of Paris), cancer genetics board of INCa (Institut National of cancer) and scientific committee of the Biomedicine Agency.

Main fields of interest: cancer genetics clinic for breast-ovarian cancers and retinoblastoma, genetic screening of the BRCA1, BRCA2, RB2, ATM, MRE11, NBN, and FANCS genes and ethical questions linked to genetic testing. She was personally involved with the Curie Institute in the opposition to the BRCA1 and BRCA2 patents obtained by Myriad Genetics to the European Patent Office. Report on PND and PGD in inherited cancers. Fields of research: (1) optimization of molecular analyses, (2) clinical and tumour characteristics of inherited breast cancers, (3) studies of chromosome breaking syndromes, (4) genetic epidemiology of breast cancer.

Research prizes and awards: Reni Fauvert Prize 1990, ligue contre le Cancer des Yvelines Prize (Yvelines Cancer League), 1999, Académie Nationale de Chirurgie Prize (French Academy of Surgery), 2002, Estie Lauder, Marie-Claire Prize – le mois du cancer du sein, 2005, Chevalier de la Ligue d'Honneur, July 14, 2006 and Henry et Mary-Jeanne Mitjaville Prize, Académie de médecine, 2007.

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Jean-Yves BLAY

SESSION 1: Public Health, Medical Management of Solid Cancers in Europe and in China

Position & affiliation: Head of Medical Oncology Department, Centre Leon Berard, Lyon, France.

Former President of European Organization for Research and Treatment of Cancer, International Agency for Research on Cancer – World Health Organization

Topic title: Epidemiology- Current and Future of Standard of Care

Jean-Yves BLAY, Scientific Director of Canceropôle Lyon Rhone-Alpes, is Professor of Medical Oncology at the University Lyon I, France. He received his M.D. in 1990 and his Ph.D. in 1994, both from the University of Lyon, France. From 1992 to 1999 Jean-Yves BLAY was Medical Oncologist, Head of the Sarcoma Committee, and Head of the Cytokine and Cancer Unit at the Leon Berard Center, Lyon, France. Between 2000 and 2004, he served as an expert at the French Agency of Health Products Safety (Agence Francaise de Securite Sanitaire des Produits de Sante, AFSSAPS). Jean- Yves BLAY is an expert member of numerous Scientific Committees including EORTC, Cancer Centers as well as Chairman of the Strategic Research Committee of the French Federation of Cancer Centers and Chairman of the Soft Tissue and Bone Sarcoma Group of EORTC. Since 2006 he has been Director of the CONTICANET Network of excellence (6th FP, European Commission). He has 406 publications, 130 last and 70 as first author.



Youlin QIAO

SESSION 1: Public Health, Medical Management of Solid Cancers in Europe and in China

Position & affiliation: Director of Cancer Epidemiology Department, National Cancer Center, CAMS/PUMC, Beijing, PRC

Topic title: Epidemiology: Attributable Causes of Cancer in China

Youlin QIAO received his M.D. in Public Health from Sichuan Medical College, Chengdu, China and his Master's Degree in Medicine from Dalian Medical College. Before returning back to China in 1997, he has been trained for 11 years at Johns Hopkins University School of Hygiene and Public Health (PhD) and Cancer Prevention Studies Branch, NCI/NIH, USA. He is director of International Collaboration Department, Cancer Foundation of China, and Deputy Director of the MOH National Expert Committee for Cancer Screening and Prevention in China. He is an author on over 400 peer reviewed publications in both English and Chinese. As an expert in cancer prevention and control, he served as WHO Director-General's Cancer Control Advisory Committee and WHO's Cancer Technical Advisory Groups for helping to promote cancer prevention and control programs in developing countries. He is involved in many national and international projects to study etiology, primary intervention, and early detection of a variety of cancers through multidisciplinary and global collaborations. He has received several national and international scientific awards, including the 2000 EUROGIN International Award, The Cornelius W. Kruse Award, The Excellent Achievement Award on Medical/Public Health Service in China and 2011 WHO/IARC Medal of Honor.

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Zefei JIANG

SESSION 2: Peripheral Blood Biomarkers

Position & affiliation: Director of Breast Cancer Department, The Hospital Affiliated To Military Medical Science, Beijing, PRC. Vice Chairman of the Chinese Anti-cancer Association Professional Committee of Chemotherapy

Topic title: Circulating Tumor Cells Predict Progression-Free and Overall Survival in Chinese Patients with Metastatic Breast Cancer, HER2-positive or Triple-negative (CBCSG004): a Multi-center, Double-blind, Prospective Trial.

Zefei JIANG, M.D. graduated in 1987 from the 1st Military Medical University, Guangzhou. In 1999, he became the Associate Professor of The Hospital Affiliated To Military Medical Science.

Then, he worked for 2 years as a visiting scientist at the Department of Medical oncology and Molecular Medicine in the City of Hope National Medical Center in USA.

Professor Zefei JIANG is an active national & international leader of several scientific organizations such as: St. Gallen Oncology Conference Chinese (Panel) anti-cancer association professional committee of chemotherapy (vice-chairman), Chinese Society of Clinical Oncology (Executive member), American Society of Clinical Oncology, etc.

He is also an Evaluation Expert in Application Guide of Anti-cancer Drug for the Chinese Ministry of Health

Research interests: A Multi-center, Prospective Study Applying Circulating Tumor Cells Detection for Metastatic Breast Cancer Patients with Cell Search Circulating Tumor Cells Detection kit to Evaluate the Prediction Ability for The Prognosis of Metastatic Breast Cancer Patients and The Consistency of Efficacy Determination between CTC Counting and Imaging. He is involved in several clinical trials as Principal Investigators or as co-Principal Investigators.

Until now, he has published a lot of publications in well-known journals such as the Journal of Clinical Oncology, Annals of oncology, etc.



Massimo CRISTOFANILLI

SESSION 2: Peripheral Blood Biomarkers

Position & affiliation: Director of the Jefferson Breast Care Center at the Kimmel Cancer Center & Thomas Jefferson University, Philadelphia, USA

Topic title: Defining the Role of Circulating Tumor Cells (CTCs) in the Liquid Phase of Epithelial Tumors

Massimo CRISTOFANILLI, M.D. has established expertise in the management of patients with advanced breast cancer, including inflammatory breast cancer (IBC). His laboratory focuses on the understanding of the molecular drivers of the metastatic process by using a number of preclinical models. The translational of these observations requires a selection and implementation of appropriate companion diagnostics. In this regard, his clinical research focus has been on the detection, characterization and possible therapeutic targeting of occult (microscopic) disease in breast cancer.

Since 1999 he led a research team to conduct collaborative efforts aimed at detection of microscopic disease in metastatic disease by using established or innovative detection/enrichment technologies. His initial work using a novel immunomagnetic-based technology (CellSearch™) led to a pivotal trial which successfully demonstrated the detection and prognostic value of circulating tumor cells (CTCs) in the peripheral blood of patients with metastatic breast cancer (MBC). The team also identified several limitations of the current detection methods based on immunomagnetic EpCAM-based assays and started to evaluate to investigate the peculiar phenotype of CTCs to improve detection. Currently, he is focusing on the biological characterization of CTCs, the link with cancer stem cells (CSCs) and their therapeutic targeting.



Paola ALLAVENA

SESSION 2: Peripheral Blood Biomarkers

Position & affiliation: Chief of Laboratory Cellular Immunology, Clinical Research Institute HUMANITAS, Mila, Italy.

Topic title: Inflammatory Chemokines and Cytokines as Prognostic Markers for Human Colorectal Cancer

Dr. Paola ALLAVENA graduated at the Medical School of the University of Milan and obtained a PhD. in Immunology. After a period at the National Cancer Institute, Frederick, National Institute of Health, MD, USA. She came back to Italy at Institute "Mario Negri", Milan as Chief of the Laboratory of Cellular Immunology. Since 2005 she is Group Leader at the Clinical Institute Humanitas. She is Author of more than 200 articles in peer-reviewed journals and ad hoc-reviewer for several international scientific journals.

Her field of interest is tumor immunology, tumor biology, inflammation and innate immunity, tumor-associated macrophages, inflammatory chemokines and cytokines, colorectal and pancreatic cancer.

She and the collaborative group, led by Professor.Mantovani, actively participated with original contributions to the identification of tumor-derived chemokines and their functional role in the tumor micro-environment, and the links between chronic inflammation and tumor progression.



Jian ZHANG

SESSION 3: Tumor Microenvironment

Position & affiliation: Executive Director, Center for Translational Medicine, Guangxi Medical University

Director, Key Laboratory of Longevity and Ageing-related Diseases, Ministry of Education, China. Adjunct Professor, University of Michigan School of Medicine

Topic title: Targeting CCL2/CCR2 Axis in Tumor Microenvironment

Dr. Jian Zhang received his PhD. in Pathology from the University of Michigan, Ann Arbor, Michigan, in 2001. Starting from 2004, he served as an assistant professor (tenure-track) at the University of Pittsburgh, and the University of Michigan (2009-2010), Department of Internal Medicine and Michigan Center for Translational Pathology. In 2011, he was invited to become a professor of Medicine and executive director of Center for Translational Medicine in Guangxi Medical University, and director of Key Laboratory of Longevity and Ageing-related Diseases, Ministry of Education, China. His research interests have been focused on the study of bidirectional and dynamic interaction between cancer cells and cells in the tumor microenvironment. He is the author/co-author of over 70 peer-reviewed publications and a reviewer for DOD panel of cancer pathobiology, Cancer Research UK Program, Australia Prostate Cancer Research Program, and National Science Foundation, China. In 2012, he was elected as an Outstanding National Scientist in China.



Elda TAGLIABUE

SESSION 3: Tumor Microenvironment

Position & affiliation: Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Topic title: Understanding Tumor-Stromal Interactions: the New Trust for Beating Cancer

with Dr. Andrea Balsari, Professor of Immunology at University of Milan, she has also begun to consider the role of the immune system in the progression and metastatic spread of breast carcinomas. She contributed with Dr. Balsari as senior author to a J Clin Oncol paper demonstrating the correlation between FOXP3 expression and worst breast cancer metastasis-free survival (Merlo et al JCO 2009).

Dr. Elda TAGLIABUE, PhD., Principal Investigator graduated with honors in Biological Sciences from the University of Milan in 1978 and began her research experience at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milan through a 3-year fellowship focused on the development of monoclonal antibodies directed against tumor-associated molecules. In 1983, she became an Associate Researcher in the Department of Experimental Oncology of Fondazione IRCCS Istituto Nazionale dei Tumori and, in 1985, a permanent staff member of this Department, continuing with the work undertaken during her fellowship period. In January 1, 2009, she became head of the Molecular Targeting Unit in the Experimental Oncology Department of Fondazione IRCCS Istituto Nazionale dei Tumori. Her research has focused mainly on the study of oncogenes and receptors of adhesion molecules involved in the progression of breast tumors. This work has produced 180 publications, 158 of which appeared in peer-reviewed specialty journals, such as Lancet, Am J Pathol, J Clin Oncol, Ann Pathol, Cancer Res, Clin Cancer Res and Oncogene for an H index of 41, demonstrating the breadth of her research as well as the integration of her work with that of other international groups. She is a member of several scientific societies, including American Association for Cancer Research, International Cancer Microenvironment Society, European Association for Cancer Research and Societm Italiana di Cancerologia.

Dr. TAGLIABUE furthered her scientific experience through collaborations and additional training periods in internationally recognized laboratories such as the Metastasis Laboratory of Liege University and The Weizmann Institute of Science of Rehovot, Israel, where she focused on the purification of adhesion molecule receptors and on the function of growth factor receptors, respectively.

Combining her expertise on oncogenes, adhesion molecules and their cognate receptors, and on components of the tumor microenvironment, Dr. TAGLIABUE now directs her research to the detection of markers able to predict the progression of breast carcinomas. In collaboration



Paul HOFMAN

SESSION 3: Tumor Microenvironment

Position & affiliation: Clinical Translation, Institute for Research on Cancer and Aging,

CNRS UMR 7284 – INSERM U1081 – UNS, Nice, France

Topic title: Crosstalk Between Neutrophils and Epithelial Cells: A New Role of the Innate Immunity in Tumor Initiation and Progression

Paul HOFMAN obtained his M.D. in 1989 at the University of Nice Sophia Antipolis (France) and his PhD. in 1994 at the University of Montpellier (France). He performed his research fellow at the Brigham and Women's Hospital in Boston (Harvard Medical School) from 1992 to 1996. During this period he worked in James Madara Pathology Laboratory focusing his interest on the pathobiology of the interaction between the neutrophils and the epithelial cells. Then he moved at the Max Planck Institut (Tubingen, Germany) working on different mechanisms of digestive carcinogenesis onset linked to a chronic inflammation.

He is full Professor in Pathology since 1995. Since 2012, he is the Head of an INSERM unit (Team 3 U1081, IRCAN) ("Chronic Inflammation and Carcinogenesis") located at the CAL Cancer Center in Nice. Moreover he is the Head of the Hospital Related Tumor Biobank of the Nice Hospital and of the Laboratory of Clinical and Experimental Pathology. He published more than 350 articles in peer-reviewed journals, 192 as a senior author. The IRCAN Team 3 works currently on different synonymous polymorphisms and on their role in different human diseases, including lung carcinoma.

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Lionel APETOH

After graduating from the "Ecole Supérieure de Biotechnologie de Strasbourg" in 2004 and obtaining a Master's degree in Life Sciences from the University of Strasbourg I, Lionel Apetoh started his research career with a PhD. in Pr Laurence Zitvogel's laboratory (Gustave Roussy Institute, Villejuif, France) where he studied the immunogenicity of tumor cell death induced by anticancer therapies. He pursued his post-doctoral research work in Dr Kuchroo's laboratory (Harvard Medical School, Boston, USA) where he studied the role of CD4 T cells in autoimmune diseases.

Thanks to the support from the French « Agence Nationale de la Recherche », he came back to France in Dijon in December 2010 to set up his own research group within Dr Francois Ghiringhelli's laboratory, research center INSERM UMR866. His current work focuses on the links between CD4 T cell differentiation and cancer.

SESSION 3: Tumor Microenvironment

Position & affiliation: Centre Georges Francois Leclerc – INSERM 866, Dijon, France

Topic title: Th17 Cells Differentiation and Anticancer Immune Response

Gaoxiang GE obtained his PhD. in 2001 at Shanghai Institute of Biochemistry.

Then he pursued his postdoctoral fellowship at the University of Tennessee, USA. He held for 5 years a position as a scientist in the pathology and lab medicine at the University of Wisconsin Madison, USA.

He decided to come back in China in 2007; currently he is Professor and Principal Investigator at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Research interests: Microenvironments of cells, via cell-cell communication, cell-extracellular matrix (ECM) interaction and growth factors retain the characteristics of cells, as well as their response to stimuli. The importance of microenvironment in pathogenesis is becoming much more recognized, from the role of ECM and matrix density in determining polarity and growth potential of cells, to the extracellular metabolism of growth factors and matrix molecules during inflammation and cancer. Accompanying growth of tumor cells, local microenvironment undergoes dynamic changes, which further facilitate uncontrolled growth of tumor cells. The long-term objective of his laboratory is to understand the cross-talk between cells and microenvironment during cancer progression and metastasis. His laboratory is particularly interested in desmoplasia occurred in many types of solid tumors, featured with fibroblast accumulation, inflammatory cell infiltration and excess matrix deposition. The work in his laboratory focuses on 1) Dynamic remodeling of ECM and its impact on cancer cells behavior; and 2) Functions of microenvironmental factors in cancer progression, metastasis and acquisition of drug resistance.



Gaoxiang GE

SESSION 3: Tumor Microenvironment

Position & affiliation: State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, PRC.

Topic title: Cancer- An Overhealing Wound: Lysyl Oxidase in Lung Fibrosis and Cancer

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Joy BURCHELL

Professor Joy BURCHELL completed her PhD. at the Imperial Cancer Research Fund (ICRF) in Professor Taylor-Papadimitriou's Laboratory.

She carried out post-doctoral work at ICRF where she was involved in the cloning of the mucin MUC1, demonstrated the presence of MUC1 in sera from cancer patients and demonstrated that MUC1 was aberrantly glycosylated in cancer. She became a Cancer Research UK Senior Scientist in 2004 and in 2007 she moved to King's College London where she is now Professor of Glyco-oncology. Professor BURCHELL is Joint Leader of the subgroup "Glycans in Cancer Biology" in the Consortium for Functional Glycomics, Joint Chairman of the International Organising Committee for the series of International Workshop on Mucins in Health & Disease, Member and temporary Deputy Chair of the Scientific Board of the Breast Cancer Campaign.

Research interests: Breast cancer; post-translational modifications; glycobiology; how changes in glycosylation in breast cancer influences metastasis; epigenetics particularly histone demethylases.

SESSION 3: Tumor Microenvironment

Position & affiliation: Breast Cancer Biology Group, Kings College London School of Medicine, Guy's Hospital, London, Great Britain

Topic title: Aberrant Glycans as Circulating and Tumours Prognostic Markers in Breast Cancer



Adelheid CERWENKA

Adelheid CERWENKA obtained her PhD. in 1995 at the Institute of Immunology, University of Vienna.

Since 2003 she is the Head of Boveri Junior Group "Innate Immunity" at the German Cancer Research Center, Heidelberg, and Venia Legendi for Immunology, University of Heidelberg, Faculty of Medicine, Heidelberg, Germany.

Since 2012 She is the Coordinator of the Study Group "NK cell" of the German Society of Immunology, member of the German Society of Immunology, Deutsche Gesellschaft für Immunologie", DGfI & Society for Natural Immunity, SNI.

SESSION 4: Role of NK Cells in Cancer Progression

Position & affiliation: Innate Immunity Group, German Cancer Research Center, Heidelberg, Germany

Topic title: Harnessing Natural Killer Cells against Cancer

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Daniel OLIVE

SESSION 4: Role of NK Cells in Cancer Progression

Position & affiliation: Immunity and Cancer department of Cancer Research Center of Marseille, and of Marseille's Cancer Research Center at the Institute Paoli Calmettes, Head of IBISA Cancer Immunomonitoring Platform, Institute Paoli-Calmettes, Marseille, France

Topic title: Recognition and Escape Mechanisms of Breast Tumor to NK cells

Daniel OLIVE is professor of immunology at Marseille School of Medicine, he is in charge of the « Immunity and Cancer » department of Cancer Research Center of Marseille, and of Marseille's Cancer Research Center at the Institute Paoli Calmettes. He is also head of IBISA Cancer Immunomonitoring Platform.

D. OLIVE has been a pioneer and leader in the co-signaling field since 1990. His work is dedicated to tumor immunology with a major emphasis on innate immunity and co-signaling molecules. His team has developed a unique expertise in co-signaling functions CD28, ICOS, PD-1, HVEM and BTLA using mAbs and recombinant proteins and identified new co-signaling molecules (BTN3A) and novel tumor escape mechanisms in NHL.



Heike KIELSTEIN

SESSION 4: Role of NK Cells in Cancer Progression

Position & affiliation: Department of Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg, Faculty of Medicine, Halle, Germany

Topic title: NK Cell Functions in Obesity and Cancer

Heike KIELSTEIN, M.D., Full Professor in the Department of Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg, Faculty of Medicine, Halle (Saale), Germany. Her field of interest is altered immune functions in obesity with a special focus on NK cell functionality in obesity and cancer. She and her national and international co-workers demonstrated attenuated NK cell activity in diet-induced obesity in both, preclinical and human studies. Among several awards, she received the Ernst-Eickhoff-Prize for Endocrinology.

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Nathalie ADDA

SESSION 5: Immunotherapy

Position & affiliation: Chief Medical Officer, Vice President, Transgene S.A, Illkirch, France

Topic title: New Immunotherapy Approaches to Treat Cancer: Two Transgene's Clinical Development

Nathalie ADDA, M.D., she is a specialist in Infectious Disease (HIV Medicine, Viral Hepatitis). She has more than 15 years of experience in the pharmaceutical industry with development expertise in all phases of clinical research through NDA and MAA filing and commercialization.

She started in the pharmaceutical industry in 1997 and in her current role as VP Medical and Regulatory and Chief Medical Officer at Transgene, Inc. she is supervising immunotherapeutic clinical programs. Prior to her current position she was Senior Medical Director and the medical lead HCV Clinical Program at Vertex Pharmaceuticals Inc. Prior to her positions in industry she was a Clinical Research Medical Monitor employed by the ANRS (National Agency for Research on AIDS & Hepatitis) where she was in charge of the Research Unit.

Overall, in this industry, her main accomplishments focused on designing, developing, planning, and managing global clinical studies, through all phases, that have led to successful registration and commercialization of therapeutics. She has handled projects for unmet medical needs that led to innovative treatments in HIV, HBV and most recently in HCV.



Maria Grazia DAIDONE

SESSION 5: Immunotherapy

Position & affiliation: Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Topic title: Potentials and Pitfalls of Circulating Biomarkers: from CTC to Micro RNAs

Maria Grazia DAIDONE graduated in Biological Sciences and Certified Board in Biostatistics at the University of Milan. She started her scientific career at Istituto Nazionale Tumori in Milan, where she is currently Head of the Biomarkers Research Unit and Director of the Department of Experimental Oncology and Molecular Medicine.

Dr.DAIDONE's authorship includes 190 articles published in peer-reviewed journals. Moreover, she acts as ad hoc-reviewer for several international scientific journals and research Foundations.

Her scientific interests are dealing with: a) biomolecular characterization of human preneoplastic and neoplastic lesions; b) identification and validation of biomarkers associated with cell proliferation, apoptosis and cell survival; c) relationship between gene expression profiles and clinical progression and/or treatment resistance in breast cancer; d) isolation, characterization and propagation of tumor-initiating cells obtained from human solid tumors; e) coordination of quality control studies for cancer biomarkers and proposition of guidelines for the clinical use of biomarkers; f) biobanking research.

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Jean-Pierre
ABASTADO

SESSION 5: Immunotherapy

Position & affiliation: Head of Tumour Immunology, Singapore Immunology Network

Topic title: Can We Improve the Traffic of Lymphocytes to the Tumor?

Jean-Pierre ABASTADO obtained a master in Mathematics and a master in Physics from Ecole Polytechnique (Paris, France). He prepared his PhD. on Major Histocompatibility Complex (MHC) at the Pasteur Institute (Paris). During his post-doctoral training at NIH (Bethesda, MD), he studied the mechanism of GCN4 translational regulation in yeast.

From 1990 to 1998, he worked at the Pasteur Institute on T cell activation and from 1998 to 2005, he was Vice-President of IDM-Pharma, a company specialized in cell therapy against cancer. From 2006 to 2013, J-P ABASTADO headed the Laboratory for Tumour Immunology within the Singapore Immunology Network (SigN/BMSI/A-STAR).



Hongxi XU

SESSION 6: Traditional Chinese Medicine for Cancer Treatment

Position & affiliation: Dean of School of Pharmacy, Shanghai University of Traditional Chinese Medicine., PRC. Recipient of "Thousand Talents Program"

Topic title: Application of Chinese Medicine in Liver and Pancreatic Cancer

Professor XU has studied and worked abroad for more than 20 years. He has been actively involved in Chinese medicine research in various institutions in Japan, Singapore, Canada and Hong Kong. In recognition of his distinguished achievements, Professor XU was selected in the sixth batch of the Thousand Talents Program (The Recruitment Program of Global Experts), and serve as a "Specially-Appointed Professor of Shanghai". Prof. XU has published more than 200 SCI papers.

His current research interest is focused on drug discovery from natural resources, as well as the development of botanical dietary supplements from herbal medicines. Specifically, Prof. XU is interested in finding natural lead compounds from medicinal plants; and in developing new drug based on Chinese medicines against different disease targets such as cancer, HSV, and cancer chemoprevention.

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Zhiqiang MENG


SESSION 6: Traditional Chinese Medicine for Cancer Treatment

Position & affiliation: Director of Integrative Oncology Department, Fudan University Shanghai Cancer Center, Adjunct Professor of M.D. Anderson Cancer Center

Topic title: Application of Chinese Medicine in Liver and Pancreatic Cancer

Zhiqiang MENG, M.D., Ph.D., is Chair of the Department of integrative oncology and professor at Fudan University Shanghai Cancer Center. He received his medical education at the Shandong Medical University and his Ph.D. at Shanghai Medical College, Fudan University. Dr. MENG's studies mainly focus on combining conventional Chinese medicine therapy and minimal invasive therapy like RF Hifu, TACE and/or on liver and pancreatic cancer. Dr. MENG has published more than 50 papers and was Principal Investigator of fundings from NIH/NCI R01 (USA) and NSFC (China).

He is also holding different functions in several scientific organizations such as: Executive member of CSCO (China Society of Clinical Oncology), Executive member of CMITO (China minimal invasive therapy organization), Chair of SMITO (Shanghai Society of Anti-Cancer minimal invasive therapy committee), Deputy Chair, China Therapeutic Ultrasound Committee.



Hailei ZHAO

SESSION 6: Traditional Chinese Medicine for Cancer Treatment

Position & affiliation: Deputy Dean of International Education College, Shanghai University of Traditional Chinese Medicine

Topic title: The Application of TCM Syndrome Differentiation to the Cancer Treatment

Dr Hailei ZHAO graduated from Shanghai University of Traditional Chinese Medicine in 1998 and got the Doctor Degree of Integrative Chinese and Western Medicine in 2002. He has been a physician in the specialty of oncology by TCM and integrative medicine and one of the members in the prominent Oncologist Dr Jiixin QIU's Team for more than 10 years. Dr ZHAO has published several articles in the field of the research on TCM treatment to cancers. His interests include the mechanism of TCM treatment on cancers such as the scientific value of applying syndrome differentiation in cancer diagnosis and treatment, the effect of treating gastric and colorectal cancers by TCM recipe, TCM education and training. He has also been the Deputy Dean in International Education College, Shanghai University of TCM since 2012.

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Xun YE

Xun YE received his Bachelor and Master degree from China Pharmaceutical University. After further training in Japan for 1 Year, Dr. YE joined Shanghai Sunway biotech Company lasting for 6 years, focused on adenovirus medicated tumor specific gene therapy. During this period, Dr. YE had been trained in United States for 6 Months, and his research was supported by China Natural Science Foundation Committee (NSFC 30371614), and he was accepted as PhD. student at the School of Medicine Shanghai JiaoTong University. Before graduation, Dr.YE was appraised as outstanding student by Baosteel Education Foundation, Shanghai Education Committee, and School of Medicine Shanghai JiaoTong University.

After receiving his PhD. degree, Dr.YE served as laboratory manager at bioMerieux from Year 2006. The joint laboratory had been set up by cooperation between Fudan University Shanghai Cancer Center and Institut Merieux, represented by two sister companies bioMerieux and Transgene. Based on the existing cooperation, the joint laboratory received grant support from European Commission: FP7- IMMUNOCAN program, starting from year 2012.

Dr. YE had achieved 25 publications in scientific journals, of which 5 had been cited as 1st author.

SESSION 7: FDUSCC-IM Joint Institute Research Activities

Position & affiliation: Lab Manager, FDUSCC-IM Joint Institute (Institut Merieux)

Topic title: Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer



Romain MICOL

Romain MICOL joined Institut Merieux group in 2008 as medical director of ABLinc based in USA and then at Shantha Biotechnics in India. He joined the R&D department of Transgene in 2010 as international scientific program manager. Previously he worked for the French national reference center for primary immunodeficiencies in France and for Pasteur Institute in France and Cambodia.

Dr. Micol received his M.D. degree from Paris VI university and his PhD. from Paris V University (France). He performed the advanced program in Management, Innovation and Technology from MIT (Cambridge,USA).

Currently Dr. MICOL is managing several programs in China in oncology and infectious diseases.

The ambitious scientific research projects in oncology in China are running in close partnership with the joint institute Fudan University Shanghai Cancer Center – Institut Merieux laboratory (FDUSCC-IM), created in May 2010. This program enlarged recently to an active partnership with Danish, Italian and German teams through IMMUNOCAN (an FP7 international cooperation program in China funded by the European Commission).

Current clinical research program is focused on immune phenotyping as a biomarker for prognosis of Chinese cancer patients, and will be extended to new types of cancer and biomarkers. These prognosis studies will help to guide clinical decision-making by facilitating the selection of appropriate treatment options.

SESSION 7: FDUSCC-IM Joint Institute Research Activities

Position & affiliation: International Scientific Program Manager, Transgene S.A

Topics titles: 1) IMMUNOCAN Program Introduction & 2) Activated NK Cells and Cytokines Signature in Stage IV NSCLC Chinese Patients: a Prognostic Study

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Romain GINESTE

Romain GINESTE joined the Institut Mirieux Group in 2012 as scientific coordinator for Transgene Biopharmaceuticals Technology Shanghai Co., Ltd. (Subsidiary of Transgene France).

He has a PhD. in Molecular Biology and Biochemistry from the University of Lille. He completed his PhD. in an industrial context within Genfit, a biopharmaceutical company specialized in drug discovery in the field of metabolic diseases. His research was focused on the mechanism of action of nuclear receptors which are therapeutic targets for atherosclerosis, type 2 diabetes and obesity. Then, he carried out a two years postdoctoral fellowship for GSK Vaccines in the department of basic immunology. His research was focused on innate molecular pathways induced by the immunostimulants. He worked on the danger/stress signals (DAMPs) induced by the GSK's adjuvants and the contribution of these signals on the adaptive immune response.

Currently, he is senior scientist for the program IMMUNOCAN at the joint laboratory Fudan University Shanghai Cancer Center-Institut Merieux.

SESSION 7: FDUSCC-IM Joint Institute Research Activities

Position & affiliation: Senior Scientist, FDUSCC-IM Joint Institute (Transgene)

Topic title: IMMUNOCAN Program for Colorectal & Breast Cancers



Ting XU

Ting XU, founder and CEO of AlphaMab in Suzhou. Dr. XU founded AlphaMab early 2009 and successfully led the company through transition from biosimilar to an innovative biotherapeutic oriented powerhouse in China. AlphaMab has so far developed and transferred several biosimilars to major pharmaceutical companies in China.

Currently, Alphamab has over 10 mAbs, including biobetter and novel, in preclinical development. Those projects cover Tumor immunotherapy, infertility and Haemophilia.

2nd Forum on Translational Medicine

Position & affiliation: CEO, President of Suzhou Alphamab Co., LTD, China

Topic title: Targeted Tumor Immunotherapeutic Development Through Antibody Engineering

1st Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology

2nd Forum on Translational Cancer Medicine

Friday 6th and Saturday 7th September 2013, Shanghai



Weiguo HU

2nd Forum on Translational Medicine

Position & affiliation: Principal Investigator of Fudan University Shanghai Cancer Center /Institutes of Biomedical Sciences (IBS), Fudan University

Topic title: Membrane Complement Regulatory Protein CD59 Confers Cancer Cells Resistance to Antibody-based Therapy: Mechanism and Strategy

Weiguo HU received his M.D. in 1997 from the Second Military Medical University, Shanghai, and served there through to 2001. In order to solid his biomedical research background; he pursued his PhD. in Biochemistry and Molecular Biology in 2004 from the Institute of Biochemistry, China Academy of Sciences, Shanghai. Afterwards, he went to Yale cancer center and Harvard Medical School and finished his postdoctoral training in 2010. Currently, Dr. HU is Professor of Cancer Immunology in Institutes of Biomedical Sciences & Shanghai Cancer Center, Fudan University. Using complement as a model system Dr. HU applies ideas and methods embodied in immunology, biochemistry, molecular biology, computer science and medicinal chemistry to study tumorigenesis and tumor therapy. Dr. HU has published over 20 papers in peer-reviewed journals such as Nature Medicine, Circulation, Blood, Cancer Research, Journal of Immunology, and applied 7 international patents. Dr. HU is also the recipient of Junior Investigator Award, the American Heart Association (AHA), U.S.A, and Travel Award, Federation of Clinical Immunology Societies (FOCIS), U.S.A. He is currently funded by the National Natural Science Foundation of China, the National Basic Research Program of China (973 Program) from Ministry of Science and Technology of China, National Key Projects from Ministry of Health of China, the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institution of Higher Learning, and Shanghai Pujiang Talent Program.



Jie LIU

2nd Forum on Translational Medicine

Position & affiliation: Chairman of Institute of the Digestive Diseases of Fudan University; Chief Physician and Director of Department of Gastroenterology of Huashan Hospital, Fudan University. "Changjiang scholar"

Topic title: From Bedside To Bench

Jie LIU, professor and chairman of Institute of the Digestive Diseases of Fudan University; chief physician and director of Gastroenterology Department of Huashan Hospital, Fudan University. He also makes an appointment of professorship with department of Immunology and Institute of Biomedical Science of Fudan University. Dr. LIU is a physician scientist with a background in basic research. He has paid more attention to translational clinical research, and published series of translational medical papers, including one in Nature Clinical Practice. This clinical study was selected as CME (continuing medical education) for clinical doctors. Dr. LIU has published more than 70 papers in international journals, including Cell, Cancer cell, The Lancet, Hepatology, Nature Clin Pract Oncol, Oncogene, Cancer research, et al.

Organizing Committee:

Jiong WU, FDUSCC, Shanghai, PRC
Romain MICOL, Transgene, France
Xingwang WAN, Shanghai International Medical Exchange Center, Shanghai, PRC
Weiguo HU, FDUSCC, Shanghai, PRC
Xi CHENG, FDUSCC, Shanghai, PRC
Zhigang CAO, FDUSCC, Shanghai, PRC
Xia MENG, Transgene, PRC
Lijun JIA, FDUSCC, Shanghai, PRC
Chunmei CAO, FDUSCC, Shanghai, PRC
Romain GINESTE, Transgene, PRC
Aissa DJOBOUNGUE, Transgene, PRC

Scientific Program Committee

Zhiming SHAO, FDUSCC, Shanghai, PRC
Sanjun CAI, FDUSCC, Shanghai, PRC
Jin LI, FDUSCC, Shanghai, PRC
Romain MICOL, Transgene, France
Xia MENG, Transgene, PRC
Mark MILLER, bioMerieux, France
Christian BRECHOT, Institut Merieux, France
Ola BLIXT, University of Copenhagen, Denmark
Roland JACOBS, Hannover Medical School, Germany
Rosaria ORLANDI, FONDAZIONE IRCCS Istituto Nazionale Dei Tumori, Milan, Italy



Add: 270 Dong An Road, Shanghai

Tel: 021-6443 8380

www.immunocan.org

交通指导(Bus) : 49、104、41、50、72、89、
864、44、712、733、932、933、814、218、
隧道二线、轨道交通4/7号线东安路站(Metro
4/7 line station Dongan)。